M&A / Deals Novo Nordisk partners OpenAI on R&D “transformation” PharmaphorumSeeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.M&A / DealsRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI. M&A / DealsRead full story Post navigation Previous: Travere Therapeutics gains FDA approval for sparsentan in FSGSNext: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026